Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nevro
MedTech
Globus Medical to buy neurostim developer Nevro for $250M
With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to a 27% premium over a 90-day weighted average.
Conor Hale
Feb 10, 2025 10:51am
Nevro lays off 5% of workforce to balance out acquisition costs
Jan 11, 2024 10:19am
Nevro's neurostim cuts diabetic neuropathy pain by 80%: study
Aug 16, 2023 11:46am
FDA approves Nevro’s AI-powered spinal cord stimulator
Oct 13, 2022 10:39am
Boston Scientific wins $20M from Nevro in patent case
Nov 3, 2021 10:15am
FDA approves Nevro’s high-frequency stimulator for diabetic pain
Jul 19, 2021 11:22am
